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The practice of medicine involves deﬁnite and random risks.
These risks relate to the unpredictable biology that we deal
with; genetic and nongenetic individual variabilities; age and
gender; compliance and environmental factors. Uniformly
applied, standard approaches to care that have been shaped
by clinical trials and modiﬁed by empiricism typically result
in desired favorable outcomes. In the best of circumstances,
though, adverse outcomes occur that need to be collectively
harnessed. As new drugs enter our pharmacopoeia, some
which are approved based on modest size clinical trials and
othersbeingused“oﬀ-label,”ourobligationforvigilanceand
reporting adverse events (AEs) increases.
Let us consider recombinant IGF-1 therapy. The number
of individuals with bonaﬁde growth hormone resistance,
the United States Food and Drug Administration (FDA)
approved indication [1], is very small [2, 3]. FDA approval
of recombinant IGF-1 was based on an experience of about
100 patients [1]. If one looks to situations where other drugs
have been recalled from the market place, safety signals
were not apparent in preapproval studies involving thou-
sands of individuals [4]( http://www.fda.gov/opacom/7alerts
.HTML; http://www.consumerjusticegroup.com/drugrecall/
drugrecalls.html). Only when the drugs hit the market place
and use was expanded by thousands more, problems leading
to withdrawal of the compounds took place.
Not long ago, a patient of ours had a life-threatening
anaphylactic reaction to recombinant IGF-1 and was sub-
sequently shown to have allergy to the preparation by a
formal testing [5]. This adverse event was reported to the
manufacturer who reported it to the FDA. Last month, I
received a call from an endocrinologist in another part of
the US describing a possible similar occurrence for this
compound, illustrating the need for further collection of
clinical experience data for new medications.
Aromatase inhibitors are used “oﬀ-label” at many pedi-
atric endocrine centers as a therapeutic for potential height
augmentation. Investigational studies of such compounds
have revealed modest, but tantalizing increases in long-
term growth [6, 7]. But with the promise comes the poise.
Vertebral abnormalities have been found in children treated
with one such compound [8]. Although further studies are
needed to assess if there are indeed adverse eﬀects of speciﬁc
aromatase inhibitors or the class of compounds in general
on the growing spine [8], it is very likely that many “oﬀ-
label” prescribers of aromatase inhibitors are not aware of
this potential problem.
Problems also rest with drugs that have been around
for so long that they may escape rereview of their safety.
Recently, a potential safety concern related to the use of
propylthiouracil was brought to the attention of Eunice
Kennedy Shriver National Institute of Child Health and
Human Development (NICHD), and a special workshop
was convened by the Obstetric and Pediatric Pharmacology
Branch (OPPB) of NICHD to look at the issue of PTU safety.
As detailed in the minutes of the meeting, a serious hepato-
toxicitysafetyconcernrelatedtoPTUuseinchildrenwasrec-
ognized(http://bpca.nichd.nih.gov/outreach/index.cfm)[9].
Thus,ittook60yearssincePTUwasintroducedbeforesafety
concerns related to the use of this compound in children
were formally addressed, highlighting the special challenges
involved in monitoring drugs that have been in the market
for decades.
It is clear that as a discipline, we need to become
proactivelyengagedindrugsafetyandmonitoringissuesand
assist pharmaceutical companies and regulatory agencies in2 International Journal of Pediatric Endocrinology
this area. It is a disservice for AEs to be hidden in clinic
ﬁles. We all need to spare a few minutes and report AEs to
the FDA, which is easily accomplished via the MedWatch
Program (http://www.medwatch.com/).
In pediatrics in the United States, we have a special
opportunity aﬀorded by the Best Pharmaceuticals for Chil-
dren Act (BPCA) Program to address such issues. The BPCA
was signed into law on January 4, 2002, to establish a
process for studying on-patent and oﬀ-patent drugs used in
children. The Obstetric and Pediatric Pharmacology Branch
(OPPB) of NICHD leads BPCA eﬀorts on behalf of the
NIH (http://bpca.nichd.nih.gov/index.cfm). As highlighted
by the recent workshop on PTU safety, it is hoped that the
Lawson Wilkins Pediatric Endocrine Society (LWPES) and
the American Academy of Pediatrics (AAP) will partner with
OPPB and NICHD and establish new ways to identify drug
and therapeutic safety concerns in our ﬁeld.
In using “on-label” or “oﬀ-label” therapies, we need to
remember a tenet of medicine “Primum non nocere” (First,
not to harm). To this credo, we must add “Secundus, opinio
vulnero” (Second, report the harm).
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